324 related articles for article (PubMed ID: 37484944)
1. GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis.
Zhang Z; Zhang Q; Tan Y; Chen Y; Zhou X; Liu S; Yu J
Front Endocrinol (Lausanne); 2023; 14():1149328. PubMed ID: 37484944
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
[TBL] [Abstract][Full Text] [Related]
3. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
Madsbad S
Diabetes Obes Metab; 2016 Apr; 18(4):317-32. PubMed ID: 26511102
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.
Yao H; Zhang A; Li D; Wu Y; Wang CZ; Wan JY; Yuan CS
BMJ; 2024 Jan; 384():e076410. PubMed ID: 38286487
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review.
Xie Z; Hu J; Gu H; Li M; Chen J
Front Endocrinol (Lausanne); 2023; 14():1244432. PubMed ID: 37701904
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: A network meta-analysis.
Chen H; Li XZ; Chen JQ; Ren TS; Zhang YS; Wang YN; Zhao QC
Medicine (Baltimore); 2023 Jul; 102(27):e34122. PubMed ID: 37417602
[TBL] [Abstract][Full Text] [Related]
7. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
Chun JH; Butts A
JAAPA; 2020 Aug; 33(S8 Suppl 1):3-18. PubMed ID: 32756220
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials.
Alkhezi OS; Alahmed AA; Alfayez OM; Alzuman OA; Almutairi AR; Almohammed OA
Obes Rev; 2023 Mar; 24(3):e13543. PubMed ID: 36579723
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Network Meta-analysis.
Jiang Y; Liu J; Chen X; Yang W; Jia W; Wu J
Adv Ther; 2021 Mar; 38(3):1470-1482. PubMed ID: 33582976
[TBL] [Abstract][Full Text] [Related]
10. Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis.
Zaccardi F; Htike ZZ; Webb DR; Khunti K; Davies MJ
Ann Intern Med; 2016 Jan; 164(2):102-13. PubMed ID: 26642233
[TBL] [Abstract][Full Text] [Related]
11. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.
Liu L; Chen J; Wang L; Chen C; Chen L
Front Endocrinol (Lausanne); 2022; 13():1043789. PubMed ID: 36568085
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.
Yuan S; Wu Y
Front Public Health; 2023; 11():1201818. PubMed ID: 37744474
[TBL] [Abstract][Full Text] [Related]
13. Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus.
Tsukamoto S; Tanaka S; Yamada T; Uneda K; Azushima K; Kinguchi S; Wakui H; Tamura K
Diabetes Obes Metab; 2024 Jan; 26(1):262-274. PubMed ID: 37828829
[TBL] [Abstract][Full Text] [Related]
14. The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.
Guo X; Zhou Z; Lyu X; Xu H; Zhu H; Pan H; Wang L; Yang H; Gong F
Horm Metab Res; 2022 Jul; 54(7):458-471. PubMed ID: 35512849
[TBL] [Abstract][Full Text] [Related]
15. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
Chun JH; Butts A
JAAPA; 2020 Aug; 33(8):3-18. PubMed ID: 32740121
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Luo Q; Wei R; Cai Y; Zhao Q; Liu Y; Liu WJ
Front Med (Lausanne); 2022; 9():793203. PubMed ID: 35280867
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysis.
Xia L; Shen T; Dong W; Su F; Wang J; Wang Q; Niu S; Fang Y
Diabetes Res Clin Pract; 2021 Jul; 177():108904. PubMed ID: 34102249
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
19. Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events.
Lingvay I; Hansen T; Macura S; Marre M; Nauck MA; de la Rosa R; Woo V; Yildirim E; Wilding J
BMJ Open Diabetes Res Care; 2020 Oct; 8(2):. PubMed ID: 33115821
[TBL] [Abstract][Full Text] [Related]
20. Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis.
Fang L; Li J; Zeng H; Liu J
Prim Care Diabetes; 2024 Jun; 18(3):268-276. PubMed ID: 38555202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
